Skip to Content
Merck
CN

1598405

USP

Ranitidine hydrochloride

United States Pharmacopeia (USP) Reference Standard

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C13H22N4O3S · HCl
CAS Number:
66357-59-3
Molecular Weight:
350.86
NACRES:
NA.24
PubChem Substance ID:
329751022
UNSPSC Code:
41116107
MDL number:
MFCD00069339

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Ranitidine hydrochloride, United States Pharmacopeia (USP) Reference Standard

InChI key

GGWBHVILAJZWKJ-CHHCPSLASA-N

SMILES string

Cl[H].CN\C(NCCSCc1ccc(CN(C)C)o1)=C\[N+]([O-])=O

InChI

1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H/b13-9-;

grade

pharmaceutical primary standard

API family

ranitidine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Ranitidine hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Ranitidine Injection
  • Ranitidine Tablets
  • Ranitidine in Sodium Chloride Injection
  • Ranitidine Oral Solution

Biochem/physiol Actions

H2 histamine receptor antagonist; anti-ulcer agent.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Travis Nemkov et al.
JCI insight, 6(3) (2020-12-23)
Computational models based on recent maps of the RBC proteome suggest that mature erythrocytes may harbor targets for common drugs. This prediction is relevant to RBC storage in the blood bank, in which the impact of small molecule drugs or
Natalia Alonso et al.
The Biochemical journal, 459(1), 117-126 (2014-01-15)
7TMRs (seven-transmembrane receptors) exist as conformational collections in which different conformations would lead to differential downstream behaviours such as receptor phosphorylation, G-protein activation and receptor internalization. In this context, a ligand may cause differential activation of some, but not all
T S Gaginella et al.
Drug intelligence & clinical pharmacy, 17(12), 873-885 (1983-12-01)
Ranitidine is a selective, competitive histamine H2-receptor antagonist recently approved by the Food and Drug Administration for use in the short-term treatment of active duodenal ulcers and gastric hypersecretory conditions. Ranitidine is four to ten times more potent than cimetidine
Question 1: does the use of ranitidine increase the risk of NEC in preterm infants?
Manigandan Chandrasekaran et al.
Archives of disease in childhood, 99(4), 390-392 (2014-03-15)
M B Evans et al.
Journal of pharmaceutical and biomedical analysis, 7(1), 1-22 (1989-01-01)
The selection, development, definition and validation of selective stability-indicating procedures for high-performance liquid chromatographic and thin-layer chromatographic analyses of ranitidine hydrochloride are described. The procedures used in conjunction can be applied to the quality assurance and stability assessments of both
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service